TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-11-14

AUTHORS

Jamie L. Croucher, Radhika Iyer, Nanxin Li, Valentina Molteni, Jon Loren, W. Perry Gordon, Tove Tuntland, Bo Liu, Garrett M. Brodeur

ABSTRACT

Purpose Neuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to relentless progression despite intensive multimodality therapy. There is compelling evidence that members of the tropomyosin receptor kinase (Trk) family play important roles in these disparate clinical behaviors. Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50–60 % of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance.Methods We tested a novel pan-Trk inhibitor, GNF-4256 (Genomics Institute of the Novartis Research Foundation), in vitro and in vivo in a nu/nu athymic xenograft mouse model to determine its efficacy in inhibiting the growth of TrkB-expressing human NB cells (SY5Y-TrkB). Additionally, we assessed the ability of GNF-4256 to enhance NB cell growth inhibition in vitro and in vivo, when combined with conventional chemotherapeutic agents, irinotecan and temozolomide (Irino–TMZ).ResultsGNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner, with an IC50 around 7 and 50 nM, respectively. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent (p < 0.0001 for mice treated at 40 or 100 mg/kg BID, compared to controls), and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino–TMZ, p < 0.0071 compared to Irino–TMZ alone).ConclusionsOur data suggest that GNF-4256 is a potent and specific Trk inhibitor capable of significantly slowing SY5Y-TrkB growth, both in vitro and in vivo. More importantly, the addition of GNF-4256 significantly enhanced the antitumor efficacy of Irino–TMZ, as measured by in vitro and in vivo growth inhibition and increased event-free survival in a mouse xenograft model, without additional toxicity. These data strongly suggest that inhibition of TrkB with GNF-4256 can enhance the efficacy of current chemotherapeutic treatment for recurrent/refractory high-risk NBs with minimal or no additional toxicity. More... »

PAGES

131-141

References to SciGraph publications

  • 2003-03. Neuroblastoma: biological insights into a clinical enigma in NATURE REVIEWS CANCER
  • 2010-08-07. K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells in INVESTIGATIONAL NEW DRUGS
  • 1999-06. Role of neurotrophins and neurotrophin receptors in the in vitro invasion and heparanase production of human prostate cancer cells in CLINICAL & EXPERIMENTAL METASTASIS
  • 1997-06. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1998-02. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma in NATURE GENETICS
  • 1995-03. A BDNF autocrine loop in adult sensory neurons prevents cell death in NATURE
  • 2004-01. Altered Expression and Activation of the Nerve Growth Factor Receptors TrkA and p75 Provide the First Evidence of Tumor Progression to Effusion in Breast Carcinoma in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-11-22. Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer in BRITISH JOURNAL OF CANCER
  • 2003-08-28. Nerve growth factor overexpression and autocrine loop in breast cancer cells in ONCOGENE
  • 2009-03-30. TrkA overexpression enhances growth and metastasis of breast cancer cells in ONCOGENE
  • 1997-01. Expression of TrkA, TrkB and TrkC in human neuroblastomas in JOURNAL OF NEURO-ONCOLOGY
  • 2006-03-29. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 1995-02. Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas in JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • 2011-10-14. More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2009-06-06. High-Throughput Screening of the Cyclic AMP-Dependent Protein Kinase (PKA) Using the Caliper Microfluidic Platform in HIGH THROUGHPUT SCREENING
  • 2011-02-22. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-05-24. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • <error retrieving object. in <ERROR RETRIEVING OBJECT
  • 2013-10-27. Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer in NATURE MEDICINE
  • Journal

    TITLE

    Cancer Chemotherapy and Pharmacology

    ISSUE

    1

    VOLUME

    75

    Related Patents

  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Molecules For Administration To Ros1 Mutant Cancer Cells
  • Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Methods For Treating Neuroblastoma
  • Combinations For The Treatment Of Neuroblastoma
  • Method Of Treatment Using Substituted Pyrazolo[1,5-A] Pyrimidine Compounds
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Method Of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Method Of Treatment Using Substituted Pyrazolo[1,5-A] Pyrimidine Compounds
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Combinations For The Treatment Of Neuroblastoma
  • Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide
  • Method Of Treatment Using Substituted Pyrazolo[1,5-A] Pyrimidine Compounds
  • Combinations For The Treatment Of Neuroblastoma
  • Substituted Pyrazolo[L,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Combinations For The Treatment Of Cancer
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Method Of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  • Method Of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Methods Of Treating Pediatric Cancers
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Pharmaceutical Compositions And Dosage Forms
  • Method Of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  • Molecules For Administration To Ros1 Mutant Cancer Cells
  • Macrocylic Compounds As Ros1 Kinase Inhibitors
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1

    DOI

    http://dx.doi.org/10.1007/s00280-014-2627-1

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1003712700

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/25394774


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Camptothecin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Survival", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dacarbazine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drugs, Investigational", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Half-Life", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Irinotecan", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Membrane Glycoproteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice, Nude", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neuroblastoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphorylation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Processing, Post-Translational", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein-Tyrosine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptor, trkB", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Temozolomide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Burden", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Xenograft Model Antitumor Assays", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.239552.a", 
              "name": [
                "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Croucher", 
            "givenName": "Jamie L.", 
            "id": "sg:person.01075773502.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075773502.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.239552.a", 
              "name": [
                "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Iyer", 
            "givenName": "Radhika", 
            "id": "sg:person.01320675661.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675661.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Li", 
            "givenName": "Nanxin", 
            "id": "sg:person.01206211573.40", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206211573.40"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Molteni", 
            "givenName": "Valentina", 
            "id": "sg:person.01135030213.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135030213.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Loren", 
            "givenName": "Jon", 
            "id": "sg:person.01364310610.59", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364310610.59"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gordon", 
            "givenName": "W. Perry", 
            "id": "sg:person.01164003500.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164003500.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tuntland", 
            "givenName": "Tove", 
            "id": "sg:person.01216641255.69", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216641255.69"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Liu", 
            "givenName": "Bo", 
            "id": "sg:person.0767173005.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767173005.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.239552.a", 
              "name": [
                "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Brodeur", 
            "givenName": "Garrett M.", 
            "id": "sg:person.015450030517.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015450030517.11"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/374450a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050386837", 
              "https://doi.org/10.1038/374450a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-011-1581-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046099568", 
              "https://doi.org/10.1007/s00280-011-1581-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/1-4020-8107-3_12", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052428201", 
              "https://doi.org/10.1007/1-4020-8107-3_12"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2012.499", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023531873", 
              "https://doi.org/10.1038/bjc.2012.499"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.3352", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040347765", 
              "https://doi.org/10.1038/nm.3352"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-012-1879-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043514230", 
              "https://doi.org/10.1007/s00280-012-1879-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-010-9513-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038591843", 
              "https://doi.org/10.1007/s10637-010-9513-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1006652605568", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048857885", 
              "https://doi.org/10.1023/a:1006652605568"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03349721", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025319217", 
              "https://doi.org/10.1007/bf03349721"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0298-184", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047807659", 
              "https://doi.org/10.1038/ng0298-184"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-005-5490-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008991250", 
              "https://doi.org/10.1007/s00018-005-5490-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1014", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008818340", 
              "https://doi.org/10.1038/nrc1014"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/b:brea.0000010704.17479.8a", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040004777", 
              "https://doi.org/10.1023/b:brea.0000010704.17479.8a"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206805", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029788448", 
              "https://doi.org/10.1038/sj.onc.1206805"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1756-9966-30-97", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037031427", 
              "https://doi.org/10.1186/1756-9966-30-97"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1005729329526", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044022705", 
              "https://doi.org/10.1023/a:1005729329526"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-60327-258-2_11", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032321217", 
              "https://doi.org/10.1007/978-1-60327-258-2_11"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2009.61", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012479383", 
              "https://doi.org/10.1038/onc.2009.61"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002800050656", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006526423", 
              "https://doi.org/10.1007/s002800050656"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-11-14", 
        "datePublishedReg": "2014-11-14", 
        "description": "Purpose\nNeuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to relentless progression despite intensive multimodality therapy. There is compelling evidence that members of the tropomyosin receptor kinase (Trk) family play important roles in these disparate clinical behaviors. Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50\u201360\u00a0% of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance.Methods\nWe tested a novel pan-Trk inhibitor, GNF-4256 (Genomics Institute of the Novartis Research Foundation), in vitro and in vivo in a nu/nu athymic xenograft mouse model to determine its efficacy in inhibiting the growth of TrkB-expressing human NB cells (SY5Y-TrkB). Additionally, we assessed the ability of GNF-4256 to enhance NB cell growth inhibition in vitro and in vivo, when combined with conventional chemotherapeutic agents, irinotecan and temozolomide (Irino\u2013TMZ).ResultsGNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner, with an IC50 around 7 and 50\u00a0nM, respectively. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent (p\u00a0<\u00a00.0001 for mice treated at 40 or 100\u00a0mg/kg BID, compared to controls), and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino\u2013TMZ, p\u00a0<\u00a00.0071 compared to Irino\u2013TMZ alone).ConclusionsOur data suggest that GNF-4256 is a potent and specific Trk inhibitor capable of significantly slowing SY5Y-TrkB growth, both in vitro and in vivo. More importantly, the addition of GNF-4256 significantly enhanced the antitumor efficacy of Irino\u2013TMZ, as measured by in vitro and in vivo growth inhibition and increased event-free survival in a mouse xenograft model, without additional toxicity. These data strongly suggest that inhibition of TrkB with GNF-4256 can enhance the efficacy of current chemotherapeutic treatment for recurrent/refractory high-risk NBs with minimal or no additional toxicity.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00280-014-2627-1", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2475910", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1088364", 
            "issn": [
              "0344-5704", 
              "1432-0843"
            ], 
            "name": "Cancer Chemotherapy and Pharmacology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "75"
          }
        ], 
        "keywords": [
          "brain-derived neurotrophic factor", 
          "high-risk neuroblastoma", 
          "additional toxicity", 
          "antitumor efficacy", 
          "tropomyosin receptor kinase (TRK) family", 
          "refractory high-risk neuroblastoma", 
          "intensive multimodality therapy", 
          "pan-Trk inhibitors", 
          "event-free survival", 
          "inhibition of TrkB", 
          "current chemotherapeutic treatment", 
          "pediatric solid tumors", 
          "vivo growth inhibition", 
          "xenograft mouse model", 
          "mouse xenograft model", 
          "human NB cells", 
          "conventional chemotherapeutic agents", 
          "dose-dependent manner", 
          "growth inhibition", 
          "disparate clinical behaviors", 
          "NB xenografts", 
          "TrkB inhibition", 
          "multimodality therapy", 
          "cell growth inhibition", 
          "TrkB phosphorylation", 
          "neuroblastoma xenografts", 
          "spontaneous regression", 
          "neurotrophic factor", 
          "relentless progression", 
          "clinical behavior", 
          "nu/", 
          "autocrine pathway", 
          "mouse model", 
          "TRK inhibitors", 
          "xenograft model", 
          "single agent", 
          "NB cells", 
          "solid tumors", 
          "clinical heterogeneity", 
          "TrkB", 
          "neuroblastoma", 
          "chemotherapeutic treatment", 
          "chemotherapeutic agents", 
          "chemotherapeutic efficacy", 
          "drug resistance", 
          "ConclusionsOur data", 
          "efficacy", 
          "xenografts", 
          "inhibition", 
          "vivo", 
          "survival", 
          "vitro", 
          "compelling evidence", 
          "inhibitors", 
          "receptor kinase family", 
          "toxicity", 
          "metastasis", 
          "temozolomide", 
          "therapy", 
          "tumors", 
          "agents", 
          "progression", 
          "important role", 
          "angiogenesis", 
          "treatment", 
          "IC50", 
          "invasion", 
          "kinase family", 
          "cells", 
          "regression", 
          "pathway", 
          "phosphorylation", 
          "nM", 
          "evidence", 
          "factors", 
          "data", 
          "growth", 
          "role", 
          "resistance", 
          "heterogeneity", 
          "manner", 
          "family", 
          "purpose", 
          "ability", 
          "addition", 
          "members", 
          "ligands", 
          "model", 
          "GNF", 
          "method", 
          "behavior", 
          "deadly pediatric solid tumors", 
          "BDNF/TrkB autocrine pathway", 
          "TrkB autocrine pathway", 
          "novel pan-Trk inhibitor", 
          "athymic xenograft mouse model", 
          "growth of TrkB", 
          "ability of GNF", 
          "NB cell growth inhibition", 
          "ResultsGNF", 
          "inhibits TrkB phosphorylation", 
          "specific Trk inhibitor", 
          "SY5Y-TrkB growth", 
          "addition of GNF", 
          "Irino\u2013TMZ", 
          "recurrent/refractory high-risk NBs"
        ], 
        "name": "TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts", 
        "pagination": "131-141", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1003712700"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00280-014-2627-1"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "25394774"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00280-014-2627-1", 
          "https://app.dimensions.ai/details/publication/pub.1003712700"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:34", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_642.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00280-014-2627-1"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1'


     

    This table displays all metadata directly associated to this object as RDF triples.

    405 TRIPLES      22 PREDICATES      176 URIs      149 LITERALS      32 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00280-014-2627-1 schema:about N01576d4652f94d5db48c04b8504c68ac
    2 N0fab4ea032ea48fc973b17ea84b4ecbc
    3 N249d2c2b639c4721999cb9b6518036d7
    4 N275cc684c5134742a3dfccba6d6ee678
    5 N2b04d4a2df86489183e8c0ac78980e69
    6 N2db89a4961ed4a34a1e94101caee13bb
    7 N3217910290f148f1b7eee6740c3a2885
    8 N3382dccb09164a548a2cd04c9d9f186d
    9 N362b73e0acd7493f80f2ca3e554cc26c
    10 N43e0b6830ede4d32b47577c7da23ac36
    11 N5567de559458494799af9beb4586e821
    12 N6273eb169b3e46229ab24e42a222f30a
    13 N644a016eb6bd4861b27d8592b48cac6b
    14 N65f3862355c0425e98d2e617a6f83a92
    15 N6893fe0497914f4e8dd983da2ec43892
    16 N7814a1acbd394157a5e5f582d1d59656
    17 N88e3e7a97a774f20b690ace57e7cd793
    18 N9023bec1f6824bc6a4e2081200f2f454
    19 N932c5bacfe2046578031e685775ebe5e
    20 Na2c051e43edd448ebb79d75fc6354528
    21 Na488b2c958124f779aaad53f004e3902
    22 Nb5e6327664bb411db4e8730365374afc
    23 Nc9444804f2a642c993595d0a81102595
    24 Ne3c2223d376b435bbcfb051e4562f829
    25 Nf41833f2de804ba0add22251bb457639
    26 anzsrc-for:11
    27 anzsrc-for:1115
    28 schema:author N1ac10020fbf747efbc15ca41bf9fc0a8
    29 schema:citation sg:pub.10.1007/1-4020-8107-3_12
    30 sg:pub.10.1007/978-1-60327-258-2_11
    31 sg:pub.10.1007/bf03349721
    32 sg:pub.10.1007/s00018-005-5490-8
    33 sg:pub.10.1007/s00280-011-1581-4
    34 sg:pub.10.1007/s00280-012-1879-x
    35 sg:pub.10.1007/s002800050656
    36 sg:pub.10.1007/s10637-010-9513-4
    37 sg:pub.10.1023/a:1005729329526
    38 sg:pub.10.1023/a:1006652605568
    39 sg:pub.10.1023/b:brea.0000010704.17479.8a
    40 sg:pub.10.1038/374450a0
    41 sg:pub.10.1038/bjc.2012.499
    42 sg:pub.10.1038/ng0298-184
    43 sg:pub.10.1038/nm.3352
    44 sg:pub.10.1038/nrc1014
    45 sg:pub.10.1038/onc.2009.61
    46 sg:pub.10.1038/sj.onc.1206805
    47 sg:pub.10.1186/1756-9966-30-97
    48 schema:datePublished 2014-11-14
    49 schema:datePublishedReg 2014-11-14
    50 schema:description Purpose Neuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to relentless progression despite intensive multimodality therapy. There is compelling evidence that members of the tropomyosin receptor kinase (Trk) family play important roles in these disparate clinical behaviors. Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50–60 % of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance.Methods We tested a novel pan-Trk inhibitor, GNF-4256 (Genomics Institute of the Novartis Research Foundation), in vitro and in vivo in a nu/nu athymic xenograft mouse model to determine its efficacy in inhibiting the growth of TrkB-expressing human NB cells (SY5Y-TrkB). Additionally, we assessed the ability of GNF-4256 to enhance NB cell growth inhibition in vitro and in vivo, when combined with conventional chemotherapeutic agents, irinotecan and temozolomide (Irino–TMZ).ResultsGNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner, with an IC50 around 7 and 50 nM, respectively. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent (p < 0.0001 for mice treated at 40 or 100 mg/kg BID, compared to controls), and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino–TMZ, p < 0.0071 compared to Irino–TMZ alone).ConclusionsOur data suggest that GNF-4256 is a potent and specific Trk inhibitor capable of significantly slowing SY5Y-TrkB growth, both in vitro and in vivo. More importantly, the addition of GNF-4256 significantly enhanced the antitumor efficacy of Irino–TMZ, as measured by in vitro and in vivo growth inhibition and increased event-free survival in a mouse xenograft model, without additional toxicity. These data strongly suggest that inhibition of TrkB with GNF-4256 can enhance the efficacy of current chemotherapeutic treatment for recurrent/refractory high-risk NBs with minimal or no additional toxicity.
    51 schema:genre article
    52 schema:inLanguage en
    53 schema:isAccessibleForFree true
    54 schema:isPartOf N3c2d48632edb4d05a4b5a1eca730e6ab
    55 Nc770a843b58849d88803a28a20922a40
    56 sg:journal.1088364
    57 schema:keywords BDNF/TrkB autocrine pathway
    58 ConclusionsOur data
    59 GNF
    60 IC50
    61 Irino–TMZ
    62 NB cell growth inhibition
    63 NB cells
    64 NB xenografts
    65 ResultsGNF
    66 SY5Y-TrkB growth
    67 TRK inhibitors
    68 TrkB
    69 TrkB autocrine pathway
    70 TrkB inhibition
    71 TrkB phosphorylation
    72 ability
    73 ability of GNF
    74 addition
    75 addition of GNF
    76 additional toxicity
    77 agents
    78 angiogenesis
    79 antitumor efficacy
    80 athymic xenograft mouse model
    81 autocrine pathway
    82 behavior
    83 brain-derived neurotrophic factor
    84 cell growth inhibition
    85 cells
    86 chemotherapeutic agents
    87 chemotherapeutic efficacy
    88 chemotherapeutic treatment
    89 clinical behavior
    90 clinical heterogeneity
    91 compelling evidence
    92 conventional chemotherapeutic agents
    93 current chemotherapeutic treatment
    94 data
    95 deadly pediatric solid tumors
    96 disparate clinical behaviors
    97 dose-dependent manner
    98 drug resistance
    99 efficacy
    100 event-free survival
    101 evidence
    102 factors
    103 family
    104 growth
    105 growth inhibition
    106 growth of TrkB
    107 heterogeneity
    108 high-risk neuroblastoma
    109 human NB cells
    110 important role
    111 inhibition
    112 inhibition of TrkB
    113 inhibitors
    114 inhibits TrkB phosphorylation
    115 intensive multimodality therapy
    116 invasion
    117 kinase family
    118 ligands
    119 manner
    120 members
    121 metastasis
    122 method
    123 model
    124 mouse model
    125 mouse xenograft model
    126 multimodality therapy
    127 nM
    128 neuroblastoma
    129 neuroblastoma xenografts
    130 neurotrophic factor
    131 novel pan-Trk inhibitor
    132 nu/
    133 pan-Trk inhibitors
    134 pathway
    135 pediatric solid tumors
    136 phosphorylation
    137 progression
    138 purpose
    139 receptor kinase family
    140 recurrent/refractory high-risk NBs
    141 refractory high-risk neuroblastoma
    142 regression
    143 relentless progression
    144 resistance
    145 role
    146 single agent
    147 solid tumors
    148 specific Trk inhibitor
    149 spontaneous regression
    150 survival
    151 temozolomide
    152 therapy
    153 toxicity
    154 treatment
    155 tropomyosin receptor kinase (TRK) family
    156 tumors
    157 vitro
    158 vivo
    159 vivo growth inhibition
    160 xenograft model
    161 xenograft mouse model
    162 xenografts
    163 schema:name TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts
    164 schema:pagination 131-141
    165 schema:productId N812e2095a3b549369f0d3d7f8c2fbfde
    166 N9f075e7590c74d11874e1a853a626274
    167 Nc999d36b1784470bb4ba50eb6c6af209
    168 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003712700
    169 https://doi.org/10.1007/s00280-014-2627-1
    170 schema:sdDatePublished 2022-01-01T18:34
    171 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    172 schema:sdPublisher Nfd0a8f8bcd05422e84531aa7d2a4137f
    173 schema:url https://doi.org/10.1007/s00280-014-2627-1
    174 sgo:license sg:explorer/license/
    175 sgo:sdDataset articles
    176 rdf:type schema:ScholarlyArticle
    177 N01576d4652f94d5db48c04b8504c68ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Tumor Burden
    179 rdf:type schema:DefinedTerm
    180 N0250abe93afd4611addf4b505444068b rdf:first sg:person.01320675661.33
    181 rdf:rest N405ded65c1c744fdace80b7e35b9d3a7
    182 N0793e22f4c8a44d8a7c5eedf7e0049b2 rdf:first sg:person.01364310610.59
    183 rdf:rest Nd8b3849218784733ae4ee39e9b4f45f7
    184 N0fab4ea032ea48fc973b17ea84b4ecbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Irinotecan
    186 rdf:type schema:DefinedTerm
    187 N199d19af0284466e80a7b8f865341117 rdf:first sg:person.01216641255.69
    188 rdf:rest Ncd0b588f51514c0eb00ed22975e48256
    189 N1ac10020fbf747efbc15ca41bf9fc0a8 rdf:first sg:person.01075773502.36
    190 rdf:rest N0250abe93afd4611addf4b505444068b
    191 N249d2c2b639c4721999cb9b6518036d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Phosphorylation
    193 rdf:type schema:DefinedTerm
    194 N275cc684c5134742a3dfccba6d6ee678 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Membrane Glycoproteins
    196 rdf:type schema:DefinedTerm
    197 N27630e4cb406494fb649b41dcd4acb21 rdf:first sg:person.015450030517.11
    198 rdf:rest rdf:nil
    199 N2b04d4a2df86489183e8c0ac78980e69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    200 schema:name Protein Processing, Post-Translational
    201 rdf:type schema:DefinedTerm
    202 N2db89a4961ed4a34a1e94101caee13bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Survival Analysis
    204 rdf:type schema:DefinedTerm
    205 N3217910290f148f1b7eee6740c3a2885 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name Xenograft Model Antitumor Assays
    207 rdf:type schema:DefinedTerm
    208 N3382dccb09164a548a2cd04c9d9f186d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Antineoplastic Agents
    210 rdf:type schema:DefinedTerm
    211 N362b73e0acd7493f80f2ca3e554cc26c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    212 schema:name Dacarbazine
    213 rdf:type schema:DefinedTerm
    214 N3c2d48632edb4d05a4b5a1eca730e6ab schema:issueNumber 1
    215 rdf:type schema:PublicationIssue
    216 N405ded65c1c744fdace80b7e35b9d3a7 rdf:first sg:person.01206211573.40
    217 rdf:rest Nfab89eb36a8040f1b002a82e33c3dc87
    218 N43e0b6830ede4d32b47577c7da23ac36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    219 schema:name Protein Kinase Inhibitors
    220 rdf:type schema:DefinedTerm
    221 N5567de559458494799af9beb4586e821 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    222 schema:name Neuroblastoma
    223 rdf:type schema:DefinedTerm
    224 N6273eb169b3e46229ab24e42a222f30a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    225 schema:name Neoplasm Proteins
    226 rdf:type schema:DefinedTerm
    227 N644a016eb6bd4861b27d8592b48cac6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    228 schema:name Dose-Response Relationship, Drug
    229 rdf:type schema:DefinedTerm
    230 N65f3862355c0425e98d2e617a6f83a92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    231 schema:name Antineoplastic Combined Chemotherapy Protocols
    232 rdf:type schema:DefinedTerm
    233 N6893fe0497914f4e8dd983da2ec43892 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    234 schema:name Camptothecin
    235 rdf:type schema:DefinedTerm
    236 N7814a1acbd394157a5e5f582d1d59656 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    237 schema:name Temozolomide
    238 rdf:type schema:DefinedTerm
    239 N812e2095a3b549369f0d3d7f8c2fbfde schema:name doi
    240 schema:value 10.1007/s00280-014-2627-1
    241 rdf:type schema:PropertyValue
    242 N88e3e7a97a774f20b690ace57e7cd793 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    243 schema:name Protein-Tyrosine Kinases
    244 rdf:type schema:DefinedTerm
    245 N9023bec1f6824bc6a4e2081200f2f454 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    246 schema:name Cell Line, Tumor
    247 rdf:type schema:DefinedTerm
    248 N932c5bacfe2046578031e685775ebe5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    249 schema:name Cell Survival
    250 rdf:type schema:DefinedTerm
    251 N9f075e7590c74d11874e1a853a626274 schema:name pubmed_id
    252 schema:value 25394774
    253 rdf:type schema:PropertyValue
    254 Na2c051e43edd448ebb79d75fc6354528 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    255 schema:name Receptor, trkB
    256 rdf:type schema:DefinedTerm
    257 Na488b2c958124f779aaad53f004e3902 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    258 schema:name Animals
    259 rdf:type schema:DefinedTerm
    260 Nb5e6327664bb411db4e8730365374afc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    261 schema:name Humans
    262 rdf:type schema:DefinedTerm
    263 Nc770a843b58849d88803a28a20922a40 schema:volumeNumber 75
    264 rdf:type schema:PublicationVolume
    265 Nc9444804f2a642c993595d0a81102595 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    266 schema:name Mice, Nude
    267 rdf:type schema:DefinedTerm
    268 Nc999d36b1784470bb4ba50eb6c6af209 schema:name dimensions_id
    269 schema:value pub.1003712700
    270 rdf:type schema:PropertyValue
    271 Ncd0b588f51514c0eb00ed22975e48256 rdf:first sg:person.0767173005.51
    272 rdf:rest N27630e4cb406494fb649b41dcd4acb21
    273 Nd8b3849218784733ae4ee39e9b4f45f7 rdf:first sg:person.01164003500.96
    274 rdf:rest N199d19af0284466e80a7b8f865341117
    275 Ne3c2223d376b435bbcfb051e4562f829 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    276 schema:name Half-Life
    277 rdf:type schema:DefinedTerm
    278 Nf41833f2de804ba0add22251bb457639 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    279 schema:name Drugs, Investigational
    280 rdf:type schema:DefinedTerm
    281 Nfab89eb36a8040f1b002a82e33c3dc87 rdf:first sg:person.01135030213.08
    282 rdf:rest N0793e22f4c8a44d8a7c5eedf7e0049b2
    283 Nfd0a8f8bcd05422e84531aa7d2a4137f schema:name Springer Nature - SN SciGraph project
    284 rdf:type schema:Organization
    285 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    286 schema:name Medical and Health Sciences
    287 rdf:type schema:DefinedTerm
    288 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    289 schema:name Pharmacology and Pharmaceutical Sciences
    290 rdf:type schema:DefinedTerm
    291 sg:grant.2475910 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-014-2627-1
    292 rdf:type schema:MonetaryGrant
    293 sg:journal.1088364 schema:issn 0344-5704
    294 1432-0843
    295 schema:name Cancer Chemotherapy and Pharmacology
    296 schema:publisher Springer Nature
    297 rdf:type schema:Periodical
    298 sg:person.01075773502.36 schema:affiliation grid-institutes:grid.239552.a
    299 schema:familyName Croucher
    300 schema:givenName Jamie L.
    301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075773502.36
    302 rdf:type schema:Person
    303 sg:person.01135030213.08 schema:affiliation grid-institutes:grid.418185.1
    304 schema:familyName Molteni
    305 schema:givenName Valentina
    306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135030213.08
    307 rdf:type schema:Person
    308 sg:person.01164003500.96 schema:affiliation grid-institutes:grid.418185.1
    309 schema:familyName Gordon
    310 schema:givenName W. Perry
    311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164003500.96
    312 rdf:type schema:Person
    313 sg:person.01206211573.40 schema:affiliation grid-institutes:grid.418185.1
    314 schema:familyName Li
    315 schema:givenName Nanxin
    316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206211573.40
    317 rdf:type schema:Person
    318 sg:person.01216641255.69 schema:affiliation grid-institutes:grid.418185.1
    319 schema:familyName Tuntland
    320 schema:givenName Tove
    321 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216641255.69
    322 rdf:type schema:Person
    323 sg:person.01320675661.33 schema:affiliation grid-institutes:grid.239552.a
    324 schema:familyName Iyer
    325 schema:givenName Radhika
    326 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675661.33
    327 rdf:type schema:Person
    328 sg:person.01364310610.59 schema:affiliation grid-institutes:grid.418185.1
    329 schema:familyName Loren
    330 schema:givenName Jon
    331 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364310610.59
    332 rdf:type schema:Person
    333 sg:person.015450030517.11 schema:affiliation grid-institutes:grid.239552.a
    334 schema:familyName Brodeur
    335 schema:givenName Garrett M.
    336 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015450030517.11
    337 rdf:type schema:Person
    338 sg:person.0767173005.51 schema:affiliation grid-institutes:grid.418185.1
    339 schema:familyName Liu
    340 schema:givenName Bo
    341 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767173005.51
    342 rdf:type schema:Person
    343 sg:pub.10.1007/1-4020-8107-3_12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052428201
    344 https://doi.org/10.1007/1-4020-8107-3_12
    345 rdf:type schema:CreativeWork
    346 sg:pub.10.1007/978-1-60327-258-2_11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032321217
    347 https://doi.org/10.1007/978-1-60327-258-2_11
    348 rdf:type schema:CreativeWork
    349 sg:pub.10.1007/bf03349721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025319217
    350 https://doi.org/10.1007/bf03349721
    351 rdf:type schema:CreativeWork
    352 sg:pub.10.1007/s00018-005-5490-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008991250
    353 https://doi.org/10.1007/s00018-005-5490-8
    354 rdf:type schema:CreativeWork
    355 sg:pub.10.1007/s00280-011-1581-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046099568
    356 https://doi.org/10.1007/s00280-011-1581-4
    357 rdf:type schema:CreativeWork
    358 sg:pub.10.1007/s00280-012-1879-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043514230
    359 https://doi.org/10.1007/s00280-012-1879-x
    360 rdf:type schema:CreativeWork
    361 sg:pub.10.1007/s002800050656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006526423
    362 https://doi.org/10.1007/s002800050656
    363 rdf:type schema:CreativeWork
    364 sg:pub.10.1007/s10637-010-9513-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038591843
    365 https://doi.org/10.1007/s10637-010-9513-4
    366 rdf:type schema:CreativeWork
    367 sg:pub.10.1023/a:1005729329526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044022705
    368 https://doi.org/10.1023/a:1005729329526
    369 rdf:type schema:CreativeWork
    370 sg:pub.10.1023/a:1006652605568 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048857885
    371 https://doi.org/10.1023/a:1006652605568
    372 rdf:type schema:CreativeWork
    373 sg:pub.10.1023/b:brea.0000010704.17479.8a schema:sameAs https://app.dimensions.ai/details/publication/pub.1040004777
    374 https://doi.org/10.1023/b:brea.0000010704.17479.8a
    375 rdf:type schema:CreativeWork
    376 sg:pub.10.1038/374450a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050386837
    377 https://doi.org/10.1038/374450a0
    378 rdf:type schema:CreativeWork
    379 sg:pub.10.1038/bjc.2012.499 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023531873
    380 https://doi.org/10.1038/bjc.2012.499
    381 rdf:type schema:CreativeWork
    382 sg:pub.10.1038/ng0298-184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047807659
    383 https://doi.org/10.1038/ng0298-184
    384 rdf:type schema:CreativeWork
    385 sg:pub.10.1038/nm.3352 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040347765
    386 https://doi.org/10.1038/nm.3352
    387 rdf:type schema:CreativeWork
    388 sg:pub.10.1038/nrc1014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008818340
    389 https://doi.org/10.1038/nrc1014
    390 rdf:type schema:CreativeWork
    391 sg:pub.10.1038/onc.2009.61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012479383
    392 https://doi.org/10.1038/onc.2009.61
    393 rdf:type schema:CreativeWork
    394 sg:pub.10.1038/sj.onc.1206805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029788448
    395 https://doi.org/10.1038/sj.onc.1206805
    396 rdf:type schema:CreativeWork
    397 sg:pub.10.1186/1756-9966-30-97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037031427
    398 https://doi.org/10.1186/1756-9966-30-97
    399 rdf:type schema:CreativeWork
    400 grid-institutes:grid.239552.a schema:alternateName Oncology Research, The Children’s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA
    401 schema:name Oncology Research, The Children’s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA
    402 rdf:type schema:Organization
    403 grid-institutes:grid.418185.1 schema:alternateName The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA
    404 schema:name The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA
    405 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...